Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Brian Curran Healy, Ph.D.

Co-Author

This page shows the publications co-authored by Brian Healy and Rohit Bakshi.
Connection Strength

7.671
  1. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 09; 27(5):481-485.
    View in: PubMed
    Score: 0.679
  2. Approaches to normalization of spinal cord volume: application to multiple sclerosis. J Neuroimaging. 2012 Jul; 22(3):e12-9.
    View in: PubMed
    Score: 0.462
  3. Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009 Nov; 80(11):1218-23.
    View in: PubMed
    Score: 0.388
  4. MRI activity in MS and completed pregnancy: Data from a tertiary academic center. Neurol Neuroimmunol Neuroinflamm. 2020 11 05; 7(6).
    View in: PubMed
    Score: 0.217
  5. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler. 2021 04; 27(4):593-602.
    View in: PubMed
    Score: 0.210
  6. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. J Neuroimaging. 2020 03; 30(2):212-218.
    View in: PubMed
    Score: 0.208
  7. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler. 2020 02; 26(2):177-187.
    View in: PubMed
    Score: 0.205
  8. The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. J Neurol Sci. 2019 Aug 15; 403:38-43.
    View in: PubMed
    Score: 0.197
  9. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 03; 6(2):e530.
    View in: PubMed
    Score: 0.194
  10. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12; 19(1):23.
    View in: PubMed
    Score: 0.194
  11. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. PLoS One. 2018; 13(11):e0206939.
    View in: PubMed
    Score: 0.191
  12. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. Brain Behav. 2018 08; 8(8):e01068.
    View in: PubMed
    Score: 0.187
  13. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15; 383:221-229.
    View in: PubMed
    Score: 0.177
  14. Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis. Int J MS Care. 2017 May-Jun; 19(3):158-164.
    View in: PubMed
    Score: 0.172
  15. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 03 01; 74(3):275-285.
    View in: PubMed
    Score: 0.170
  16. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Nov; 127(11):971-980.
    View in: PubMed
    Score: 0.169
  17. The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging. 2016 10 05; 16(1):56.
    View in: PubMed
    Score: 0.165
  18. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol. 2016; 7:99.
    View in: PubMed
    Score: 0.162
  19. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 2017 May; 127(5):396-403.
    View in: PubMed
    Score: 0.161
  20. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis. J Neurol. 2016 Mar; 263(3):531-8.
    View in: PubMed
    Score: 0.157
  21. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2016 Mar-Apr; 26(2):184-7.
    View in: PubMed
    Score: 0.154
  22. T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. BMC Neurol. 2015 Jul 31; 15:124.
    View in: PubMed
    Score: 0.152
  23. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Nov; 262(11):2425-32.
    View in: PubMed
    Score: 0.152
  24. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. Neuroimage Clin. 2015; 8:606-10.
    View in: PubMed
    Score: 0.151
  25. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. J Neuroimaging. 2016 Jan-Feb; 26(1):62-7.
    View in: PubMed
    Score: 0.151
  26. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. Neuroimage. 2015 Oct 01; 119:81-8.
    View in: PubMed
    Score: 0.151
  27. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 01; 25(14):1156-61.
    View in: PubMed
    Score: 0.144
  28. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. J Neurol Sci. 2014 Nov 15; 346(1-2):250-4.
    View in: PubMed
    Score: 0.143
  29. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
    View in: PubMed
    Score: 0.119
  30. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
    View in: PubMed
    Score: 0.113
  31. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15; 303(1-2):109-13.
    View in: PubMed
    Score: 0.111
  32. Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
    View in: PubMed
    Score: 0.100
  33. Normal findings on brain fluid-attenuated inversion recovery MR images at 3T. AJNR Am J Neuroradiol. 2009 May; 30(5):911-6.
    View in: PubMed
    Score: 0.098
  34. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. J Neurol Sci. 2009 Apr 15; 279(1-2):99-105.
    View in: PubMed
    Score: 0.098
  35. 3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis. Neuroimage. 2009 Jul 01; 46(3):633-41.
    View in: PubMed
    Score: 0.098
  36. Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis. J Neurol Sci. 2009 Mar 15; 278(1-2):54-9.
    View in: PubMed
    Score: 0.096
  37. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
    View in: PubMed
    Score: 0.096
  38. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
    View in: PubMed
    Score: 0.095
  39. Early Predictors of Clinical and MRI Outcomes Using Least Absolute Shrinkage and Selection Operator (LASSO) in Multiple Sclerosis. Ann Neurol. 2022 07; 92(1):87-96.
    View in: PubMed
    Score: 0.061
  40. Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS. Mult Scler J Exp Transl Clin. 2022 Jan-Mar; 8(1):20552173211069348.
    View in: PubMed
    Score: 0.059
  41. Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. Mult Scler J Exp Transl Clin. 2021 Apr-Jun; 7(2):20552173211015503.
    View in: PubMed
    Score: 0.057
  42. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021 06; 89(6):1195-1211.
    View in: PubMed
    Score: 0.057
  43. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. J Neuroimaging. 2021 03; 31(2):388-393.
    View in: PubMed
    Score: 0.056
  44. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020 06; 7(6):945-955.
    View in: PubMed
    Score: 0.053
  45. Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019 Dec 11; 2(1):123.
    View in: PubMed
    Score: 0.051
  46. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Dec; 5(12):1478-1491.
    View in: PubMed
    Score: 0.047
  47. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci. 2018 Sep; 12:42-46.
    View in: PubMed
    Score: 0.047
  48. Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis. J Neurol Sci. 2018 09 15; 392:94-99.
    View in: PubMed
    Score: 0.047
  49. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult Scler Relat Disord. 2017 Oct; 17:47-53.
    View in: PubMed
    Score: 0.043
  50. Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One. 2017; 12(4):e0174866.
    View in: PubMed
    Score: 0.043
  51. Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors. J Neuroimaging. 2015 Mar-Apr; 25(2):191-199.
    View in: PubMed
    Score: 0.036
  52. One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
    View in: PubMed
    Score: 0.028
  53. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am J Neuroradiol. 2011 Mar; 32(3):515-21.
    View in: PubMed
    Score: 0.028
  54. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):75-9.
    View in: PubMed
    Score: 0.026
  55. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. AJNR Am J Neuroradiol. 2009 Oct; 30(9):1731-9.
    View in: PubMed
    Score: 0.025
  56. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.